762 related articles for article (PubMed ID: 21471811)
1. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
2. Therapy switching in patients receiving long-acting opioids.
Berger A; Hoffman DL; Goodman S; Delea TE; Seifeldin R; Oster G
Ann Pharmacother; 2004 Mar; 38(3):389-95. PubMed ID: 14742831
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
5. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
7. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K
Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190
[TBL] [Abstract][Full Text] [Related]
9. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
[TBL] [Abstract][Full Text] [Related]
10. [Three-day-type transdermal fentanyl patch conversion by rapid titration method with short-acting oral oxycodone for cancer pain].
Yamazaki K; Fujio N; Ishikawa N; Watanabe H; Kameyama M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):405-8. PubMed ID: 22421768
[TBL] [Abstract][Full Text] [Related]
11. Predictors of long-acting opioid use and oral versus transdermal route among older Medicaid beneficiaries.
Rigler SK; Shireman TI; Kallenbach L
Am J Geriatr Pharmacother; 2007 Jun; 5(2):91-9. PubMed ID: 17719511
[TBL] [Abstract][Full Text] [Related]
12. [A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer].
Ikeda M; Sonoo H; Kurebayashi J; Oota Y; Fujii S; Shimo T; Mizutou A; Seki M; Saitou W; Yamashita T; Koike Y; Yamamoto Y; Shiiki S; Nakashima K; Tanaka K; Nomura T; Kubo S
Gan To Kagaku Ryoho; 2012 Apr; 39(4):599-603. PubMed ID: 22504685
[TBL] [Abstract][Full Text] [Related]
13. [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl].
Fujimoto M; Sakuyama T; Mizutani Y; Kuroda T; Yanaga K
Gan To Kagaku Ryoho; 2004 Dec; 31 Suppl 2():190-3. PubMed ID: 15645768
[TBL] [Abstract][Full Text] [Related]
14. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain.
Tani M; Fuku A; Terashita S; Kashiwagi H; Yukawa H; Yamaue H
Hepatogastroenterology; 2008; 55(86-87):1545-8. PubMed ID: 19102339
[TBL] [Abstract][Full Text] [Related]
15. Indication of Adequate Transdermal Fentanyl Dose in Opioid Switching From Oral Oxycodone in Patients With Cancer.
Matsumura C; Yamada M; Fujihara S; Chisaki Y; Takahashi K; Yano Y
Am J Hosp Palliat Care; 2016 Mar; 33(2):109-14. PubMed ID: 25324418
[TBL] [Abstract][Full Text] [Related]
16. Inconsistencies in opioid equianalgesic ratios: clinical and research implications.
O'Bryant CL; Linnebur SA; Yamashita TE; Kutner JS
J Pain Palliat Care Pharmacother; 2008; 22(4):282-90. PubMed ID: 21923312
[TBL] [Abstract][Full Text] [Related]
17. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
[TBL] [Abstract][Full Text] [Related]
18. Rapid switching between transdermal fentanyl and methadone in cancer patients.
Mercadante S; Ferrera P; Villari P; Casuccio A
J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations].
Akiyama Y; Iseki M; Izawa R; Ishii K; Miyazaki T; Yamaguchi S; Tani Y
Masui; 2007 Mar; 56(3):317-23. PubMed ID: 17366919
[TBL] [Abstract][Full Text] [Related]
20. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Botterman J; Criel N
Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
